An integrin αvβ3 antagonistic modified peptide inhibits tumor growth through inhibition of the ERK and AKT signaling pathways.
第一作者:
Lirong,Hu
第一单位:
The Engineering Research Center of Peptide Drug Discovery and Development, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China.
作者:
医学主题词
动物(Animals);抗肿瘤药(Antineoplastic Agents);细胞系, 肿瘤(Cell Line, Tumor);细胞运动(Cell Movement);细胞增殖(Cell Proliferation);鸡胚(Chick Embryo);女(雌)性(Female);人类(Humans);整合素αVβ3(Integrin alphaVbeta3);MAP激酶信号系统(MAP Kinase Signaling System);小鼠(Mice);小鼠, 近交BALB C(Mice, Inbred BALB C);小鼠, 裸(Mice, Nude);新生血管化, 病理性(Neovascularization, Pathologic);寡核苷酸序列分析(Oligonucleotide Array Sequence Analysis);寡肽类(Oligopeptides);聚乙烯二醇类(Polyethylene Glycols);聚合酶链反应(Polymerase Chain Reaction);原癌基因蛋白质c-akt(Proto-Oncogene Proteins c-akt);大鼠(Rats);信号传导(Signal Transduction);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)
DOI
10.3892/or.2016.4994
PMID
27499314
发布时间
2018-12-02
- 浏览140
Oncology reports
1953-62页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



